How to Value an Ophthalmology Practice in 2026

Ophthalmology has become one of the most aggressively acquired physician specialties in the country, and the reasons are straightforward. Cataract surgery is the highest-volume outpatient surgical procedure in America — over 4 million performed annually — with an aging population that guarantees growing demand for the next two decades. Layer on cash-pay refractive surgery, ASC ownership economics, and a fragmented market of solo and small-group practices, and you have everything PE firms look for in a roll-up thesis.

I've worked on ophthalmology transactions ranging from solo cataract surgeons to 20-provider multi-state platforms, and the valuation spread is enormous. A solo ophthalmologist selling to a younger colleague might get 2-3x SDE. That same practice, if it has the right characteristics, could attract a PE-backed platform willing to pay 8-12x EBITDA. Understanding what separates those two outcomes is what this guide is about.

Why PE Loves Ophthalmology

Before diving into valuation methods, it's worth understanding why ophthalmology commands some of the highest multiples in physician practice M&A. The thesis rests on four pillars.

Demographics are destiny.The 65+ population — the primary cataract surgery demographic — will grow by 30% over the next 15 years. This isn't a cyclical demand story. It's a structural one that gives acquirers confidence in long-term revenue visibility.

Procedure mix is favorable. Ophthalmology uniquely combines Medicare-reimbursed surgical volume (cataracts, glaucoma) with high-margin cash-pay procedures (LASIK, PRK, premium IOLs). That blend of payer-insulated revenue and elective cash revenue is rare in medicine and extremely attractive to buyers.

ASC economics create leverage. Ophthalmologists who own or co-own ambulatory surgery centers capture the facility fee in addition to the professional fee, effectively doubling the revenue per procedure. ASC ownership is the single biggest differentiator in ophthalmology valuations.

The market is fragmented. Despite a decade of consolidation, the majority of ophthalmology practices are still independent. Major platforms like EyeCare Partners, US Eye, and Unifeye Vision Partners have hundreds of locations but have barely scratched the surface of the total market.

Valuation Ranges: What I See in the Market

Ophthalmology practice valuations span a wide range, and the primary drivers are practice size, ASC ownership, and the balance between surgical and clinical revenue.

• Solo/small group (1-3 MDs), no ASC: 2-3x SDE or 5-7x EBITDA. These are typically clinic-only practices generating $500K-$2M in net revenue per provider. Without ASC income, the margin profile doesn't support premium multiples.
• Mid-size group (4-8 MDs), with ASC: 7-10x EBITDA. This is the sweet spot for PE platform acquisitions. The ASC generates facility fees that boost EBITDA materially, the practice has enough providers to survive any one departure, and there's a clear path to operational improvement.
• Large group (9+ MDs), multi-location, ASC ownership: 10-14x EBITDA for platform deals. At this scale, buyers are paying for a management team, geographic density, and the ability to serve as the anchor for a regional or national roll-up.
• Retina and glaucoma sub-specialists: Command a 10-20% premium within their size bracket because of higher procedure reimbursement and even stronger demographic tailwinds.

Cataract Volume: The Core Value Driver

In ophthalmology M&A, cataract surgery volume is the metric that matters most. Buyers will analyze your cataract volume per surgeon, your conversion rate from diagnosis to surgery, and your premium IOL adoption rate with more intensity than almost any other financial metric.

A productive cataract surgeon performs 800-1,200 cases per year. Surgeons at the high end of that range — consistently above 1,000 — are generating significantly more revenue per provider than the market average, and buyers pay accordingly. But they also want to see that the volume is sustainable and not dependent on a single referral source.

Premium IOL adoptionis the margin accelerator. When a patient opts for a premium intraocular lens (multifocal, toric, extended depth of focus) instead of a standard monofocal, the out-of-pocket upgrade ranges from $1,500 to $4,000 per eye. That's pure cash-pay revenue layered on top of the Medicare-reimbursed surgical fee. Practices with 25-35% premium IOL adoption rates command meaningfully higher multiples than those at 10-15%. Buyers view it as a proxy for the practice's sales culture and patient education capabilities.

ASC Ownership: The Multiplier Effect

I cannot overstate how much ASC ownership affects ophthalmology valuations. A cataract surgeon operating at a hospital outpatient department or a third-party ASC captures only the professional fee — roughly $800-$1,200 per case under Medicare. The same surgeon performing the same procedure in an ASC they own also captures the facility fee — another $1,000-$1,800 per case.

For a surgeon doing 1,000 cataracts per year, that's an additional $1M-$1.8M in facility fee revenue, with margins of 40-60% after ASC operating expenses. ASC EBITDA of $500K-$1M per surgeon is common in well-run ophthalmology ASCs. When buyers apply their EBITDA multiple to the combined practice and ASC earnings, the valuation impact is transformative.

Practices that don't own an ASC but have the volume to justify one still benefit — buyers will model the ASC development opportunity into their valuation, though they'll apply a discount for the 12-18 months of build-out and regulatory approval required.

LASIK and Refractive Revenue

LASIK and PRK revenue is pure cash-pay, which makes it among the most valuable revenue a medical practice can generate. No insurance authorization, no claim denials, no collection lag. Patients pay $2,000-$5,000 per eye at the time of service.

Practices with meaningful refractive revenue ($500K+ annually) attract a different valuation lens from buyers. The refractive business is valued almost like a consumer services company — on margin, patient acquisition cost, and growth rate — rather than on traditional medical practice metrics. Buyers who understand this will pay a premium because refractive revenue is insulated from Medicare reimbursement risk, which is the single biggest structural threat to ophthalmology practice values.

The flip side: refractive volume is sensitive to economic cycles and consumer confidence. Practices that are 40%+ dependent on LASIK/PRK revenue will see some multiple compression because buyers discount for that cyclicality. The ideal mix, from a valuation standpoint, is 60-70% surgical (cataract/glaucoma), 15-25% refractive, and the balance in medical ophthalmology.

What Kills Ophthalmology Practice Value

Single-surgeon dependency.If you are the only surgeon and you perform all the cataracts, buyers face a binary risk — if you leave or become disabled, the practice's surgical revenue goes to zero. Adding even one associate surgeon who handles 20-30% of cases can increase your practice value by 15-25%.

Referring OD dependency. Many ophthalmology practices rely on optometrist referrals for their surgical pipeline. If 50%+ of your cataract referrals come from 2-3 OD offices, buyers will discount for concentration risk. Building an employed or co-managed OD network diversifies this risk and increases value.

Aging equipment. Ophthalmology is equipment-intensive. A femtosecond laser, diagnostic OCT suite, and phaco machines represent $500K-$1.5M in capital equipment. If your equipment is approaching end of life, buyers will deduct replacement costs from their offer.

Declining surgical volume. Two years of declining cataract volume is a red flag that suggests market saturation, referral loss, or surgeon aging. Buyers will extrapolate the trend forward and price accordingly.

The Bottom Line

Ophthalmology practice valuation in 2026 is driven by surgical volume, ASC ownership, and procedure mix. Practices with high cataract volume, owned ASCs, meaningful refractive revenue, and multiple surgeons are commanding 10-14x EBITDA from PE-backed platforms. Solo surgeons without ASC ownership are looking at 2-3x SDE from private buyers. The gap between those two outcomes is enormous, and closing it requires deliberate planning 2-4 years before you want to exit. If you're an ophthalmologist considering a sale, the single highest-ROI move you can make is developing an ASC. Nothing else comes close.